870072-61-0

Basic information

• Product Name: Benzenamine, 2-(3,4-dihydro-4,4-dimethyl-1(2H)-quinolinyl)-
• CAS NO: 870072-61-0
• Molecular Formula: C17H20N2
• Molecular Weight: 252.359
• Mol File: 870072-61-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-(3,4-dihydro-4,4-dimethyl-1(2H)-quinolinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-(3,4-dihydro-4,4-dimethyl-1(2H)-quinolinyl)-(870072-61-0)
• EPA Substance Registry System: Benzenamine, 2-(3,4-dihydro-4,4-dimethyl-1(2H)-quinolinyl)-(870072-61-0)

Safety Data

• Hazardous Substances Data: 870072-61-0(Hazardous Substances Data)

Upstream product

• 20364-31-2 4,4-dimethyl-1,2,3,4-tetrahydroquinoline 
• 76693-04-4 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one 
• 13209-80-8 N-phenyl-3-methyl-2-butenamide 
• 3350-78-5 3,3-Dimethylacryloyl chloride 
• 62-53-3 aniline 
• 870072-60-9 4,4-dimethyl-1-(2-nitro-phenyl)-1,2,3,4-tetrahydroquinoline 

Downstream Products

• 917898-56-7 1-benzoyl-3-(2-(4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)phenyl)thiourea 

Relevant articles and documents

Conformationally constrained ortho- Anilino diaryl ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.